CR20120108A - ANTIBODIES AGAINST THE EXTODOMINUM OF ERBB3 AND USES OF THE SAME - Google Patents

ANTIBODIES AGAINST THE EXTODOMINUM OF ERBB3 AND USES OF THE SAME

Info

Publication number
CR20120108A
CR20120108A CR20120108A CR20120108A CR20120108A CR 20120108 A CR20120108 A CR 20120108A CR 20120108 A CR20120108 A CR 20120108A CR 20120108 A CR20120108 A CR 20120108A CR 20120108 A CR20120108 A CR 20120108A
Authority
CR
Costa Rica
Prior art keywords
erbb3
receptor
extodominum
same
antibodies against
Prior art date
Application number
CR20120108A
Other languages
Spanish (es)
Inventor
Birgit Schoeberl
Ulrik Nielsen
Michael Feldhaus
Original Assignee
Merrimack Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43607614&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20120108(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merrimack Pharmaceuticals Inc filed Critical Merrimack Pharmaceuticals Inc
Publication of CR20120108A publication Critical patent/CR20120108A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona una nueva clase de anticuerpos y fragmentos de unión a antígeno de los mismos que se unen al dominio extracelular del receptor ErbB3 e inhiben diversas funciones de ErbB3. Por ejemplo, los anticuerpos y fragmentos de unión a antígeno descritos en la presente son capaces de unirse al receptor designado ErbB3 e inhibir la fosforilación mediada por ligando similar a EGF del receptor.The present invention provides a new class of antibodies and antigen-binding fragments thereof that bind to the extracellular domain of the ErbB3 receptor and inhibit various functions of ErbB3. For example, the antibodies and antigen binding fragments described herein are capable of binding to the receptor designated ErbB3 and inhibiting EGF-like ligand-mediated phosphorylation of the receptor.

CR20120108A 2009-08-21 2012-03-05 ANTIBODIES AGAINST THE EXTODOMINUM OF ERBB3 AND USES OF THE SAME CR20120108A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23579909P 2009-08-21 2009-08-21

Publications (1)

Publication Number Publication Date
CR20120108A true CR20120108A (en) 2012-06-05

Family

ID=43607614

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20120108A CR20120108A (en) 2009-08-21 2012-03-05 ANTIBODIES AGAINST THE EXTODOMINUM OF ERBB3 AND USES OF THE SAME

Country Status (21)

Country Link
EP (1) EP2467164A2 (en)
JP (1) JP5752687B2 (en)
KR (1) KR20120059568A (en)
CN (1) CN103002912A (en)
AU (1) AU2010284018C1 (en)
BR (1) BR112012003809A2 (en)
CA (1) CA2771744A1 (en)
CR (1) CR20120108A (en)
DO (1) DOP2012000044A (en)
EA (1) EA201200195A1 (en)
EC (1) ECSP12011740A (en)
IL (1) IL218097A0 (en)
IN (1) IN2012DN01518A (en)
MA (1) MA33582B1 (en)
MX (1) MX336091B (en)
NI (1) NI201200027A (en)
PE (1) PE20121585A1 (en)
SG (1) SG178509A1 (en)
TN (1) TN2012000057A1 (en)
WO (1) WO2011022727A2 (en)
ZA (1) ZA201201195B (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101598229B1 (en) 2007-02-16 2016-02-26 메리맥 파마슈티컬즈, 인크. 3 antibodies against erbb3 and uses thereof
MX357972B (en) * 2009-11-13 2018-08-01 Amgen Inc Material and methods for treating or preventing her-3 associated diseases.
ES2571226T3 (en) 2009-12-22 2016-05-24 Roche Glycart Ag Anti-HER3 antibodies and uses thereof
JP2013522237A (en) 2010-03-11 2013-06-13 メリマック ファーマシューティカルズ インコーポレーティッド Use of ERBB3 inhibitors in the treatment of triple negative and basal-like breast cancer
BR112012025730B1 (en) 2010-04-09 2020-12-08 Aveo Pharmaceuticals, Inc isolated antibody that binds to human erbb3, its uses, its production process and expression vector
CU24094B1 (en) 2010-08-20 2015-04-29 Novartis Ag ANTIBODIES FOR THE RECEIVER 3 OF THE EPIDERMAL GROWTH FACTOR (HER3)
TW201302793A (en) 2010-09-03 2013-01-16 Glaxo Group Ltd Novel antigen binding proteins
IT1402149B1 (en) * 2010-10-04 2013-08-28 Ist Fisioterap Ospitalroma USE OF A PHOSPHOPEPTIDE WHICH IS ABLE TO BLOCK THE HER3 / P85 INTERACTION FOR THE TREATMENT OF HER2 EXPRESSION TUMORS.
US9217039B2 (en) 2010-11-01 2015-12-22 Symphogen A/S Anti-HER3 antibodies and compositions
CN103703026B (en) 2011-04-19 2015-08-26 梅里麦克制药股份有限公司 Monospecific and the anti-IGF-1R of dual specific and anti-ERBB3 antibody
KR20140033152A (en) 2011-06-20 2014-03-17 교와 핫꼬 기린 가부시키가이샤 Anti-erbb3 antibody
US9273143B2 (en) 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
SG11201400150TA (en) 2011-09-30 2014-03-28 Regeneron Pharma Anti-erbb3 antibodies and uses thereof
CN103959065B (en) 2011-10-06 2018-07-17 Aveo制药公司 Predict the response of tumour confrontation ERBB3 antibody
JP6149042B2 (en) * 2011-11-09 2017-06-14 ザ ユーエービー リサーチ ファンデーション HER3 antibody and use thereof
EA202092280A3 (en) 2011-12-05 2021-09-30 Новартис Аг ANTIBODIES TO EPIDERMAL GROWTH FACTOR 3 (HER3) RECEPTOR
JP2015509492A (en) * 2012-02-22 2015-03-30 ユー３・ファーマ・ゲーエムベーハー Combination of HB-EGF binding protein and EGFR inhibitor
AR094403A1 (en) 2013-01-11 2015-07-29 Hoffmann La Roche ANTI-HER3 ANTIBODY COMBINATION THERAPY
WO2015058108A1 (en) * 2013-10-17 2015-04-23 Sanford-Burnham Medical Research Institute Drug sensitivity biomarkers and methods of identifying and using drug sensitivity biomarkers
WO2015100459A2 (en) 2013-12-27 2015-07-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
JP6771385B2 (en) * 2014-02-28 2020-10-21 メルス ナムローゼ フェンノートシャップ Bispecific antibody and pharmaceutical composition
CN105367657B (en) * 2014-08-14 2019-09-13 上海生物制品研究所有限责任公司 Anti- HER3 antibody, its preparation method and its application
WO2016038609A1 (en) * 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Anti-her3 antibodies and uses of same
WO2016038610A1 (en) 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki)
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
PL3365373T3 (en) 2015-10-23 2021-08-23 Merus N.V. Binding molecules that inhibit cancer growth
CN110650752A (en) 2017-03-31 2020-01-03 美勒斯公司 ErbB-2 and ErbB3 binding bispecific antibodies for treating cells with NRG1 fusion gene
SG11202001050PA (en) 2017-08-09 2020-03-30 Merus Nv Antibodies that bind egfr and cmet
EP3665200A4 (en) 2017-08-09 2021-04-28 University of Saskatchewan Her3 binding agents and uses thereof
GB201804094D0 (en) * 2018-03-14 2018-04-25 Ultrahuman Thirteen Ltd ERBB3 Binding agents
WO2019241893A2 (en) * 2018-06-22 2019-12-26 Crd Pharmaceuticals Inc Anti-her3 antibody and uses thereof
CN116133694A (en) * 2020-10-14 2023-05-16 江苏恒瑞医药股份有限公司 anti-HER 3 antibody and anti-HER 3 antibody drug conjugate and medical application thereof
WO2023198138A1 (en) * 2022-04-13 2023-10-19 上海翰森生物医药科技有限公司 Antibody or antigen-binding fragment thereof and medical use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101598229B1 (en) * 2007-02-16 2016-02-26 메리맥 파마슈티컬즈, 인크. 3 antibodies against erbb3 and uses thereof

Also Published As

Publication number Publication date
MA33582B1 (en) 2012-09-01
IN2012DN01518A (en) 2015-06-05
NI201200027A (en) 2013-01-29
ZA201201195B (en) 2015-07-29
BR112012003809A2 (en) 2019-09-24
TN2012000057A1 (en) 2013-09-19
MX2012002172A (en) 2012-05-29
CA2771744A1 (en) 2011-02-24
CN103002912A (en) 2013-03-27
WO2011022727A2 (en) 2011-02-24
EA201200195A1 (en) 2012-12-28
EP2467164A2 (en) 2012-06-27
AU2010284018B2 (en) 2014-06-05
WO2011022727A3 (en) 2013-06-27
DOP2012000044A (en) 2012-06-30
AU2010284018A1 (en) 2012-03-22
MX336091B (en) 2016-01-08
JP2013506622A (en) 2013-02-28
ECSP12011740A (en) 2013-02-28
PE20121585A1 (en) 2012-11-29
KR20120059568A (en) 2012-06-08
JP5752687B2 (en) 2015-07-22
AU2010284018C1 (en) 2015-10-15
SG178509A1 (en) 2012-04-27
IL218097A0 (en) 2012-04-30

Similar Documents

Publication Publication Date Title
CR20120108A (en) ANTIBODIES AGAINST THE EXTODOMINUM OF ERBB3 AND USES OF THE SAME
ECSP099637A (en) ANTIBODIES AGAINST ERBB3 AND THE USES OF THE SAME
CR20140146A (en) ANTI-BODIES ANTI-CD134 (OX40) AND USES OF THE SAME
CY1118761T1 (en) CODES FOR RECEPTORING GROWTH FACTORS 3 (HER3)
CY1121862T1 (en) ANTI-PHF-TAU ANTIBODIES AND USES THEREOF
PE20171041A1 (en) CD3 / CD38 T-CELL REDIRECTION HETERO-DIMERIC IMMUNOGLOBULINS AND THEIR PRODUCTION METHODS
CO2017006740A2 (en) Anti-cd79b antibodies
BR112018070919A2 (en) anti-tim-3 antibodies and compositions
CR20150498A (en) ANTI-BODIES OF ANTI-CD134 (OX40) HUMANIZED AND USES OF THE SAME
CR20110566A (en) IMMUNOCONJUGADOS OF ANTIMESOTELINA AND USES OF THE SAME
CO2018003452A2 (en) Bispecific antibodies against human cd20 and human transferrin receptor and methods of use
CY1121673T1 (en) NEUTRALIZING ANTIBODIES TO THE MAJOR EXOTOXINS TCDA AND TCDB OF CLOSTRIDIUM DIFFICILE INFECTION
CL2017002641A1 (en) Bispecific antibody constructs against cdh3 and cd3
CY1119154T1 (en) ANTI-VLA-4 ANTIBODIES
CR20120577A (en) ANTIBODIES TO GDF8 HUMAN
BR112016000903A2 (en) antibodies
BR112017022838A2 (en) kappa myeloma antigen chimeric antigen receptors and their uses
BR112016007112A2 (en) ANTIBODIES THAT BINDS HUMAN ANGIOPOIETIN 2 (ANG-2), USES OF AN ANTIBODY THAT BINDS HUMAN ANGIOPOIETIN 2 (ANG-2) AND COMBINATION
TR201905458T4 (en) Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of their use.
CY1121167T1 (en) IMPROVED ANTIBODIES AGAINST HUMAN FRACTALKIN AND THEIR USES
BR112013025917A2 (en) Use of a masp-2 antibody or fragment thereof that inhibits masp-2-dependent complement activation
CU20140073A7 (en) COMPOSITIONS AND METHODS FOR ANTIBODIES ACTING ON FACTOR P
UY36942A (en) ANTIGEN UNION PROTEINS THAT ACTIVATE THE LEPTINE RECEIVER
CU20150181A7 (en) ANTIBODIES OF LEXINED OXIDATED LDL RECEIVER 1
CY1120732T1 (en) INHIBITORS H4 RECEPTORS FOR TREATMENT